You are here:

fondaparinux (Arixtra)


In the absence of a submission from the holder of the marketing authorisation.

fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the prevention of venous thromboembolic events (VTE) in medical patients who are judged to be at high risk of VTE and who are immobilised due to acute illness, such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infections or inflammatory disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Drug Details

Drug Name: fondaparinux (Arixtra)
SMC Drug ID: 261/06
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Prevention of venous thromboembolic events
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 8 May 2006